Moscow Exchange · GEMA · RAS
Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov: revenue, profit and cash flow
In 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov had revenue of ₽349M and a net profit of ₽151M, according to its single-entity RAS statements (without subsidiaries). Here: 2 years of annual reports since 2023, each linked to the original document.
Revenue, 2024
change against 2023
Where the money goes
Of every ₽100 of revenue in 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov spent ₽16.8 on the cost of its products and services and ₽32.0 on running the business (₽32.0 of it on selling and administration); ₽0.0 went to income tax, ₽7.7 went to interest and other items, and ₽43.4 was left as net profit.
| In 2024 | Amount | Of revenue |
|---|---|---|
| Revenue | ₽349M | 100.0% |
| Cost of revenue | −₽58.7M | 16.8% |
| Gross profit | ₽290M | 83.2% |
| Sales & admin | −₽112M | 32.0% |
| Operating profit | ₽178M | 51.1% |
| Income tax | ₽-0 | 0.0% |
| Interest and other, net | −₽26.9M | 7.7% |
| Net profit | ₽151M | 43.4% |
In 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov took in ₽248M of cash from its operations. Of every ₽100 of it, it spent ₽4.3 on capital expenditure and ₽62.0 on dividends. The remaining ₽33.8 was left for other uses: repaying debt, investments or the cash balance.
| In 2024 | Amount | Of operating cash |
|---|---|---|
| Operating cash flow | ₽248M | 100.0% |
| Capital expenditure | −₽10.6M | 4.3% |
| Free cash flow | ₽237M | 95.7% |
| Dividends | −₽153M | 62.0% |
| Left over | ₽83.6M | 33.8% |
Revenue and net profit
Revenue went from ₽284M in 2023 to ₽349M in 2024.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was ₽237M in 2024, 68.0% of revenue.
What it owns and who paid for it
At the end of 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov had ₽1.24B of assets, ₽277M of it in cash. They were paid for by ₽240M of borrowings, ₽692M of other liabilities and ₽304M of shareholders' equity: equity is 24.6% of the assets.
Net debt
At the end of 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov had more cash than borrowings: net cash of ₽36.8M.
Dividends paid
In 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov paid ₽153M in dividends, 101% of its net profit for the year.
The charts could not be loaded; the table below has the same numbers.
Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov: annual figures
| Year | Revenue | Operating profit | Net profit | Operating cash flow | Capital expenditure | Free cash flow | Net debt | Dividends paid | Total assets | Equity |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | ₽349M | ₽178M | ₽151M | ₽248M | ₽10.6M | ₽237M | −₽36.8M | ₽153M | ₽1.24B | ₽304M |
| 2023* | ₽284M | ₽149M | ₽126M | ₽224M | ₽14.2M | ₽210M | ₽43.8M | ₽123M | ₽1.28B | ₽441M |
* Taken from the comparative column of the next year's report: the year's own report was not available to us.
Original reports
Every figure on this page comes from the company's own annual statements. The documents, by year:
- 2024 — RAS financial statements (single entity)
How to read these numbers
- Only single-entity RAS statements are available for this company: they cover the parent company alone, without its subsidiaries, and are not comparable with group IFRS figures.
- A year's figures are as first reported. Companies sometimes restate the previous year in their next report (new accounting standards, discontinued operations); the original documents show both versions.
Source: annual financial statements published by Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov (links to the original documents above). Figures read from the documents by BigCapital.
For information only, not investment advice.